Dansk Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-06-2024
- Paid Up Capital ₹ 1.50 M
as on 16-06-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.25 M
as on 16-06-2024
- Revenue 2.85%
(FY 2022)
- Profit -196.20%
(FY 2022)
- Ebitda -216.74%
(FY 2022)
- Net Worth -577.29%
(FY 2022)
- Total Assets 249.15%
(FY 2022)
About Dansk Pharmaceuticals India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹5.25 M.
Bhagat Singh, Urmila Pandey, Sunil Kumar, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24230HR2020PTC086501
- Company No.
086501
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Faridabad, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dansk Pharmaceuticals India?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Urmila Pandey  | Director | 20-Jan-2021 | Current |
| Bhagat Singh | Director | 15-May-2022 | Current |
| Sunil Kumar | Director | 02-Jun-2020 | Current |
| Kuldeep Sangwan | Director | 02-Jun-2020 | Current |
| Gautam Gupta | Director | 02-Jun-2020 | Current |
| Harinder Singh | Director | 01-Feb-2021 | Current |
Financial Performance and Corporate Structure Insights of Dansk Pharmaceuticals India.
Dansk Pharmaceuticals India Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 2.85% increase. The company also saw a substantial fall in profitability, with a 196.2% decrease in profit. The company's net worth observed a substantial decline by a decrease of 577.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dansk Pharmaceuticals India?
In 2022, Dansk Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Mar 2022 | ₹5.25 M | Open |
How Many Employees Work at Dansk Pharmaceuticals India?
Dansk Pharmaceuticals India has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dansk Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dansk Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
